Garland SM

Dimech W

Collignon P

Cooley L

Nimmo GR

Smith DW

Baird, Robert

Rawlinson W

Costa A-M

Higgins G

2018-07-30

Along with the reduction in human papillomavirus (HPV) infection and cervical abnormalities as a result of the successful HPV vaccination program, Australia is adopting a new screening strategy. This involves a new paradigm moving from cervical cytological screening to molecular nucleic acid technology (NAT), using HPV DNA assays as primary screening for cervical cancer prevention. These assays must strike a balance between sufficient clinical sensitivity to detect or predict high-grade cervical lesions, the precursor to cervical cancer, without being too sensitive and detecting transient infection not destined for disease. Ensuring the highest quality HPV NAT is thus a priority in order to reduce the possibility of falsely negative screens and manage the risk associated with false positive HPV NAT results. How to do this needs informed discussion and ongoing refinement of the screening algorithm. This is of relevance as more countries move to more sensitive HPV NAT tests for secondary prevention of cervical cancer and as more HPV assays become available. This article is protected by copyright. All rights reserved.

Department of Microbiology & Infectious Diseases, Royal Women's Hospital, Parkville, Australia.. Murdoch Childrens Research Institute, Parkville, Australia.. Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia..

National Serology Reference Laboratory, Australia (NRL), Fitzroy, Australia..

Infectious Diseases and Microbiology, Canberra Hospital, Australia.. Medical School. Australian National University, PO, Australia..

Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Australia.. Pathology Queensland Central Laboratory, Herston, Australia.. Griffith University School of Medicine, Southport, Australia.. PathWest Laboratory Medicine WA, Nedlands, WA, Australia.. Faculty of Health and Medical Sciences, University of Western Australia, Nedlands, WA, Australia.. Territory Pathology, Infectious Diseases, Royal Darwin Hospital, Department of Health and Families, Australia.. Virology, Serology and OTDS Laboratories, NSW Health Pathology, Randwick, NSW, Australia.. The Royal Children's Hospital, Parkville, Australia.. Microbiology and Infectious Disease, South Australia Pathology, Adelaide, SA, Australia..

Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Australia..

Pathology Queensland Central Laboratory, Herston, Australia.. Griffith University School of Medicine, Southport, Australia..

PathWest Laboratory Medicine WA, Nedlands, WA, Australia.. Faculty of Health and Medical Sciences, University of Western Australia, Nedlands, WA, Australia..

Territory Pathology, Infectious Diseases, Royal Darwin Hospital, Department of Health and Families, Australia..

Virology, Serology and OTDS Laboratories, NSW Health Pathology, Randwick, NSW, Australia..

Department of Microbiology & Infectious Diseases, Royal Women's Hospital, Parkville, Australia.. The Royal Children's Hospital, Parkville, Australia..

Microbiology and Infectious Disease, South Australia Pathology, Adelaide, SA, Australia..

J Pathol Clin Res . 2018 Oct;4(4):207-212. doi: 10.1002/cjp2.110. Epub 2018 Sep 11.

0000-0002-6869-311X

https://pubmed.ncbi.nlm.nih.gov/30058126/?otool=iaurydwlib

https://hdl.handle.net/10137/7019

HPV

NAT

quality assurance

quality control

The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality.

Journal Article

Publication